Immune cells take on sarcoma in early trial
NCT ID NCT04052334
First seen Feb 25, 2026 · Last updated Jun 13, 2026 · Updated 15 times
Summary
This early-phase trial tested a treatment that uses a patient's own immune cells (called TILs) to fight soft tissue sarcoma. Nine young adults received chemotherapy to prepare their bodies, then an infusion of their own TILs plus high-dose IL-2 to boost the immune response. The main goal was to see if the treatment was safe and if the TILs could survive in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.